EUVIMEDEUVIMED entdecken
Crossref

Cyclosporine-A Nanotherapeutics Ameliorate Lupus Nephritis by Reprogramming the Gut-Microbial Metabolic Axis and Systemic Inflammation

Kabirat T Babalola, Raghu Ganugula iD, Meenakshi Arora iD, Sandeep K Agarwal, Chandra Mohan, Babak J Mehrara, M N V Ravi Kumar iD

ACS Nano · 2026

DOI: 10.1021/acsnano.6c03606 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Kabirat T Babalola und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, AIME Building, Box 870204, Tuscaloosa, Alabama35401, United Stat…. Hauptthemen laut MEDLINE: Lupus Nephritis, Cyclosporine, Gastrointestinal Microbiome, Inflammation. Die Arbeit nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease fueled by abnormal immune responses and metabolic dysregulation, often leading to life-threatening lupus nephritis (LN). While Cyclosporine A (CsA) is a potent therapeutic agent, its clinical utility is severely constrained by systemic off-target toxicity and the necessity for frequent, high-dose administration. This study evaluates P2Ns-GA-CsA, a receptor-mediated, targeted nanoparticle formulation designed to modulate the core immune-metabolic axis in LN. Using an NZBWF1/J murine model, the administration of P2Ns-GA-CsA achieves enhanced renal protection compared to conventional oral CsA (Neoral), effectively suppressing serum creatinine, clusterin, and proinflammatory cytokines while preserving renal histoarchitecture. This therapeutic efficacy is realized with less than half the dosing frequency of the clinical standard, requiring 42 doses versus 98 doses over a 14 week period. Mechanistically, P2Ns-GA-CsA treatment is associated with the restoration of gut microbial homeostasis through the enrichment of protective taxa (Lactobacillus and Muribaculaceae), facilitating a metabolic shift. This modulation of the gut-microbial metabolic axis promotes the anti-inflammatory indole pathway while suppressing the pathogenic indoleamine 2,3-dioxygenase 1 (IDO1)-kynurenine pathway. These findings demonstrate that this targeted nanotherapeutic strategy decouples the immunosuppressive benefits of CsA from its systemic toxicity while restoring gut-renal integrity in autoimmune disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus NephritisCyclosporineGastrointestinal MicrobiomeInflammationNanoparticlesImmunosuppressive AgentsAnimalsMiceFemaleDisease Models, Animal

Stichwörter der Autor:innen

cyclosporinegut dysbiosislupus nephritissystemic lupus erythematosustryptophan metabolism

Substanzen

CyclosporineImmunosuppressive Agents

Autor:innen und Institutionen

  • The Center for Convergent Bioscience and Medicine (CCBM), The University of Alabama, AIME Building, Box 870204, Tuscaloosa, Alabama35401, United States.
  • Department of Translational Science and Medicine, College of Community Health Sciences, The University of Alabama, Tuscaloosa, Alabama35401, United States.
  • Alabama Life Research Institute, The University of Alabama, Tuscaloosa, Alabama35401, United States.
  • Department of Biological Sciences, The University of Alabama, SEC 1325, Tuscaloosa, Alabama35401, United States.
  • Nephrology Research and Training Center, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama35294, United States.
  • Section of Immunology, Allergy and Rheumatology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, Texas77030, United States.

ORCID-Profile: Raghu Ganugula, Meenakshi Arora, M N V Ravi Kumar

Zitieren

APA

Babalola, K. T., Ganugula, R., Arora, M., Agarwal, S. K., Mohan, C., Mehrara, B. J., & Kumar, M. N. V. R. (2026). Cyclosporine-A Nanotherapeutics Ameliorate Lupus Nephritis by Reprogramming the Gut-Microbial Metabolic Axis and Systemic Inflammation. ACS Nano. https://doi.org/10.1021/acsnano.6c03606

Vancouver

Babalola KT, Ganugula R, Arora M, Agarwal SK, Mohan C, Mehrara BJ, et al. Cyclosporine-A Nanotherapeutics Ameliorate Lupus Nephritis by Reprogramming the Gut-Microbial Metabolic Axis and Systemic Inflammation. ACS Nano. 2026. doi:10.1021/acsnano.6c03606

BibTeX
@article{Babalola2026,
  author = {Babalola, Kabirat T and Ganugula, Raghu and Arora, Meenakshi and Agarwal, Sandeep K and Mohan, Chandra and Mehrara, Babak J and Kumar, M N V Ravi},
  title = {Cyclosporine-A Nanotherapeutics Ameliorate Lupus Nephritis by Reprogramming the Gut-Microbial Metabolic Axis and Systemic Inflammation},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.6c03606}
}
Kostenlos starten →